Gene therapy system and method using alpha-msh and its derivatives
OwnerJames M Lipton, Anna P Cataniainventors
Life of this patent
Estimating the term…
Abstract
Disclosed in this specification is the use alpha-MSH and/or its derivatives as an adjunct to gene therapy. In one aspect, the gene therapy vector includes nucleic acids that expresses alpha-MSH and/or its derivatives. Inflammatory or immune response gene promoter may control the expression of alpha-MSH and/or its derivatives. The sequences may also be expressed together with a therapeutic gene using an internal ribosomal entry site sequence. In another aspect, pharmacologically effective amount of alpha-MSH and/or its derivatives may be administered before, after, or concurrently with the gene therapy vector carrying the appropriate gene.
Claims19
A gene therapy system comprising:
- a gene therapy vector having at least one therapeutic gene or nucleic acid;
- and
- a pharmacologically effective amount of α-MSH and/or its derivatives associated with the gene therapy vector.
A method of gene therapy comprising:
- administering a pharmacologically effective amount of α-MSH and/or its derivatives before, after, or concurrently with the administration of a gene therapy vector having at least one therapeutic gene or nucleic acid.
Dependencies are inferred from the claim text.